Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07060456

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07060456
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07060456. Randomized; triple masking; primary purpose treatment. Start 2025-07-25 (actual); primary completion 2027-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Intervention (Drug)
HRS9531
Intervention (Drug)
HRS9531
Intervention (Drug)
Placebo
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07060456
Content hash
0433d435ffb6fac48c764e0092a6a441b325d2d4a9c5657ad98bc1d155a7896e